论文部分内容阅读
肝细胞癌(hepatocellular carcinoma,HCC)是世界上最常见的癌症之一.然而,就目前现状而言,HCC的治疗效果还很有限.作为一个依赖于烟酰胺腺嘌呤二核苷酸(NAD+)的去乙酰化酶,SIRT1(silent mating type information regulation 2 homolog 1)参与了代谢、应激反应、衰老以及肿瘤的演进等许多重要的生物学进程.临床研究显示,SIRT1在HCC患者中异常高表达,并可预测其不良预后;进一步的研究表明,SIRT1在HCC演进中发挥了关键作用,且作用范围广泛,分子机制复杂.这提示,SIRT1有望成为新的HCC治疗靶点和诊断、预后标志物.本文拟对SIRT1在HCC的演进和预后中的具体作用及其潜在分子机制作一总结,并就SIRT1作为肝癌治疗靶点和诊断、预后标志物的可行性做出探讨.
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world.However, HCC is still limited in its present state of the art.As a HCC-dependent adenocarcinoma (NAD +), SIRT1 participates in many important biological processes such as metabolism, stress response, senescence, tumor progression, etc. SIRT1 is abnormally highly expressed in HCC patients , And can predict its adverse prognosis.Further studies have shown that SIRT1 plays a key role in the evolution of HCC and has a wide range of molecular mechanisms and complexity.This suggests that SIRT1 is expected to become a new therapeutic target and diagnosis of HCC, a prognostic marker This article intends to summarize the specific role of SIRT1 in the development and prognosis of HCC and its potential molecular mechanisms and to explore the feasibility of using SIRT1 as a target for the treatment of liver cancer and for the diagnosis and prognostic markers.